carboplatin,pemetrexed,durvalumab,paclitaxel,cisplatin,gemcitabine,pembrolizumab,vinorelbine,nivolumab,docetaxel,ipilimumab
astrazeneca,merck,bms
['durva', 'aegean', 'kn-671', 'pembro']
 i suspect many oncs will favor a regimen that has (future) fda approval for post-op year of io "baked in" to the overall plan they would start with. for this reason, i think kn-671/pembro (or poss durva based on aegean, though to my eye this is not as impressive) will be favored.
Med Onc,@CityofHope; VP Netwk Strategy AccessHope, Founder,@CancerGRACE; Web Ed,@JAMAOnc; Author/Ed, @UptoDate

Telemed/digital med fan. 
Disclosures @ website